化疗期间体重增加与晚期非小细胞肺癌患者的结果之间的关系
Eric J Roeland1, Florian J Fintelmann2, Fiona Hilton3
1Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.
Journal of cachexia, sarcopenia and muscle
|March 12, 2024
概括
接受化疗的非小细胞肺癌患者的体重增加与较低的死亡风险有关. 任何体重增加,即使超过0%,也可能预测更好的生存结果.
科学领域:
- 在瘤学瘤学.
- 临床研究 临床研究
- 癌症治疗方法 癌症治疗方法
背景情况:
- 研究非小细胞肺癌 (NSCLC) 的预后因素对于治疗优化至关重要.
- 基于的化疗是高级NSCLC的标准一线治疗方法.
研究的目的:
- 分析接受一线化疗的NSCLC患者体重增加类别和整体存活率 (OS) 之间的关联.
- 为了确定体重增加是否可以作为早期生存预测因素.
主要方法:
- 来自三项III期临床试验的对照组的聚合分析.
- 在治疗的前3个月内最大体重增加 (>0%,>2.5%,>5.0%) 的分类.
- 考克斯的比例危险建模来评估OS的危险比率 (HRs),调整共变量和响应.
主要成果:
- 在1030名NSCLC患者中,44%的患者体重增加>0%,24.5%的患者体重增加>2.5%,11.7%的患者体重增加>5.0%.
- 任何体重增加 (>0%,>2.5%,>5.0%) 与死亡风险显著降低有关 (HRs从0.71到0.77).
- 与没有体重增加的患者相比,体重增加的患者的中位数寿命显著更长.
结论:
- 在NSCLC治疗期间体重增加是降低死亡率的独立预测因素,无论瘤反应如何.
- 在不同体重增加门 (>0%,>2.5%,>5.0%) 上,生存益处是一致的.
- 这些发现表明,监测体重增加可以为癌症缓解症干预提供信息,并改善生存预测.
更多相关视频
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
1.1K
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.5K
相关概念视频
01:21Cancer Survival Analysis
345
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
345
02:49Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
163
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
163
02:53Adaptive Mechanisms in Cancer Cells
5.8K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.8K